AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8584682
Drug: Fluspirilene 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluspirilene 0.5 mg per week
Trial: 8584682
Drug: Fluspirilene 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluspirilene 1.0 mg per week
Trial: 8584682
Drug: Fluspirilene 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluspirilene 1.5 mg per week
Trial: 8584682
Drug: Test therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test therapy (initial response after 2 weeks)
Trial: 637427
Drug: High-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber diet (20 g of crude fiber)
Trial: 637427
Drug: Low-fiber diet
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber diet (3 g of crude fiber)
Trial: 31318075
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy with lenient definitions of remission
Trial: 31318075
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy with stringent definitions of remission
Trial: 19458055
Drug: Satraplatin administered
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satraplatin administered orally at 80 mg/m² once daily for 5 consecutive days every 5 weeks (fasted state)
Trial: 19458055
Drug: Satraplatin administered
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satraplatin administered in fed state on day 1 and day 5 of cycle 1
Trial: 19458055
Drug: Satraplatin administered
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Satraplatin administered in fasted state for subsequent cycles
Trial: 15641642
Drug: Acute poisonings
RxNorm normalized name: poison ivy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute poisonings via inhalation
Trial: 15641642
Drug: Pharmaceutical poisons
RxNorm normalized name: poison ivy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical poisons
Trial: 11391226
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day RAD
Trial: 11391226
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day RAD
Trial: 11391226
Drug: 4 mg/day
RxNorm normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/day RAD
Trial: 9266292
Drug: Palliative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative physical treatment
Trial: 2878953
Drug: Tertatolol 5
RxNorm normalized name: tertatolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol 5 mg orally
Trial: 2878953
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg orally
Trial: 30114973
Drug: Isometric leg
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isometric leg press training at L-MTU (knee angle 85°)
Trial: 30114973
Drug: Both training
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both training groups (S-MTU and L-MTU)
Trial: 20347079
Drug: Crinone vaginal
RxNorm normalized name: Crinone Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone vaginal gel
Trial: 18541303
Drug: Alcohol ingestion
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol ingestion (0.59+/‐0.07 g/kg body weight)
Trial: 10962113
Drug: Hyperglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemic clamp at 10 mmol/l in non-diabetic twins
Trial: 23859673
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg IV qd followed by 400 mg PO qd
Trial: 23859673
Drug: Ampicillin-sulbactam 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam 1.5 g IV qid followed by 750 mg PO q12h
Trial: 23859673
Drug: Ampicillin-sulbactam therapy
RxNorm normalized name: ampicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam therapy
Trial: 20556561
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg + Hydrochlorothiazide 12.5 mg
Trial: 8971294
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g sucralfate
Trial: 27040041
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg every 8 hours for 2 months)
Trial: 25400056
Drug: Photodynamic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic antimicrobial therapy with Fufanghuangbai liquid wet dressing and semiconductor laser irradiation (20 min twice daily for 7 days)
Trial: 23715447
Drug: Intraligamentous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentous injections with 4% articaine with epinephrine
Trial: 7026344
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g/day (short-term)
Trial: 7026344
Drug: Pirenzepine 75
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 75 mg/day (short-term)
Trial: 7026344
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg at bedtime (long-term)
Trial: 7026344
Drug: Pirenzepine 30
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 30 mg at bedtime (long-term)
Trial: 26553006
Drug: Phytosterols and
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols and inulin-enriched soymilk (2 g/day of phytosterols and 10 g/day of inulin)
Trial: 19688627
Drug: Resistant Starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Starch (RS) 25 g daily for 14 days
Trial: 19688627
Drug: Wheat Bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat Bran (WB) 25 g daily for 14 days
Trial: 8988907
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn as zinc methionine
Trial: 8988907
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn + 20 mg Fe
Trial: 8506732
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (5 x 2 Gy)
Trial: 8506732
Drug: High-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiotherapy (10 x 2 Gy or 5 x 3.5 Gy)
Trial: 8506732
Drug: Low-dose vs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vs High-dose radiotherapy
Trial: 3651109
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 100 mg t.i.d. for 120 days
Trial: 29984567
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) based on NeckPix©, 4 sessions, 1-week duration
Trial: 29984567
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) based on Tampa Scale of Kinesiophobia (TSK), 4 sessions, 1-week duration
Trial: 18314433
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to a second, different SSRI (paroxetine, citalopram, or fluoxetine, 20‐40 mg)
Trial: 18314433
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to venlafaxine (150‐225 mg)
Trial: 18314433
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to a different SSRI plus cognitive behavioral therapy
Trial: 18314433
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to venlafaxine plus cognitive behavioral therapy
Trial: 18314433
Drug: Medication switch
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switch alone
Trial: 12202662
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/m²/d) and LV (90 mg/d) for 28 days every 35 days
Trial: 12202662
Drug: 5-FU (425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) IV for 5 days every 35 days
Trial: 10599909
Drug: Full-mouth scaling
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth scaling plus systemic metronidazole and amoxicillin and supragingival irrigation with chlorhexidine digluconate
Trial: 7495241
Drug: Multivitamin and
RxNorm normalized name: Multivitamin and Minerals Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin and multimineral supplements
Trial: 6130074
Drug: Alcohol (1
RxNorm normalized name: POLYVINYL ALCOHOL (18000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1 g/kg) with Buspirone
Trial: 30995972
Drug: Atrasentan 0·75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 0·75 mg orally daily
Trial: 30768615
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP) mass drug administration (MDA)
Trial: 28103942
Drug: Fipronil/(S)-methoprene combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fipronil/(S)-methoprene combination
Trial: 23173698
Drug: Lead-in twice-daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lead-in twice-daily interferon-β/ribavirin therapy (IFN-β)
Trial: 23173698
Drug: PEG-IFN/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFN/ribavirin therapy (PEG)
Trial: 19568011
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BtX‐A) injection
Trial: 19568011
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline solution (placebo)
Trial: 11711490
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (estradiol valerate 1 mg daily; n=7)
Trial: 2889654
Drug: Betaxolol 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol 0.5% Ophthalmic Solution
Trial: 28746977
Drug: Adjuvant fluorouracil/folinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant fluorouracil/folinic acid (FUFA) chemotherapy
Trial: 27388615
Drug: losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 100 mg once daily
Trial: 27388615
Drug: spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone 25 mg once daily
Trial: 23640393
Drug: BOMP (bleomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOMP (bleomycin 7 mg days 1‐5, vincristine 0.7 mg m(‐2) day 5, mitomycin 7 mg m(‐2) day 5, cisplatin 14 mg m(‐2) days 1‐5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group)
Trial: 20689583
Drug: Dihydroartemisinin-piperaquine (DHA/PQP);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DHA/PQP); adults: 40 mg/320 mg; children: 20 mg/160 mg; n = 769
Trial: 20689583
Drug: Artesunate-mefloquine (AS+MQ);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (AS+MQ); AS: 50 mg, MQ: 250 mg; n = 381
Trial: 14552594
Drug: 0.2% brimonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% brimonidine eye drops given twice daily for 30 days
Trial: 31967736
Drug: Collagen combination
RxNorm normalized name: collagen, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen combination material (collagen cone and collagen membrane)
Trial: 28088030
Drug: metformin 500mg
RxNorm normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 500mg bid
Trial: 28088030
Drug: metformin 1000mg
RxNorm normalized name: METFORMIN 1000MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 1000mg bid
Trial: 28088030
Drug: linagliptin 2.5mg/metformin
RxNorm normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 2.5mg/metformin 500mg bid
Trial: 28088030
Drug: linagliptin 2.5mg/metformin
RxNorm normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 2.5mg/metformin 1000mg bid
Trial: 28088030
Drug: linagliptin 2.5mg/metformin
RxNorm normalized name: LINAGLIPTIN 2.5MG/METFORMIN HCL 500MG TAB,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin 2.5mg/metformin 1000mg bid (severe hyperglycemia group)
Trial: 25414262
Drug: AL-IVM1 (AL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-IVM1 (AL plus single dose of ivermectin 200 µg/kg)
Trial: 25414262
Drug: AL-IVM2 (AL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-IVM2 (AL plus repeated dose of ivermectin 200 µg/kg)
Trial: 21809664
Drug: Systemic chemo-infusion
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemo-infusion with oxaliplatin (FOLFOX)
Trial: 21809664
Drug: Regional chemo-infusion
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional chemo-infusion with irinotecan (FOLFIRI)
Trial: 21809664
Drug: Systemic chemo-infusion
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemo-infusion
Trial: 21809664
Drug: Regional chemo-infusion
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional chemo-infusion
Trial: 19728751
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg once daily for 10 days followed by 10 mg once daily for 10 days, along with aspirin 75 mg daily
Trial: 19728751
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg maintenance dosing
Trial: 19728751
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg maintenance dosing
Trial: 16961674
Drug: Specific anticoagulant
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific anticoagulant prescription forms
Trial: 16146551
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 8-12 ng/mL (GI)
Trial: 16146551
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 15-20 ng/mL (GII)
Trial: 12966414
Drug: Irinotecan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 200 mg/m² i.v. (1-h infusion) on day 1, L-leucovorin 250 mg/m² i.v. (1-h infusion) plus 5-fluorouracil 850 mg/m² i.v. bolus on day 2 every 2 weeks (IRIFAFU)
Trial: 10218721
Drug: Temocapril 20
RxNorm normalized name: temocapril
DrugBank: Temocapril (DB08836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril 20 mg daily (n = 19)
Trial: 2095610
Drug: clobutinol syrup
RxNorm normalized name: clobutinol
DrugBank: Clobutinol (DB09004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clobutinol syrup (Silomat, Boehringer, Ingelheim)
Trial: 508075
Drug: Positional feedback
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positional feedback stimulation training (PFST) in addition to conventional treatment
Trial: 31591187
Drug: CDK4/6 inhibitor
RxNorm normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitor palbociclib and fulvestrant
Trial: 29641247
Drug: Capsella bursa‐pastoris
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsella bursa‐pastoris capsules (dosage: 2 capsules every 12 hours)
Trial: 29641247
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (500 mg, dosage: 2 capsules every 8 hours) + placebo
Trial: 29207980
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavior therapy (CaCBTp), 12 weekly sessions
Trial: 29207980
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behavior therapy (CaCBTp)
Trial: 26255892
Drug: Cefepime and
RxNorm normalized name: cefepime and amikacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime and amoxicillin/clavulanic acid combination therapy
Trial: 26255892
Drug: Tigecycline-based therapy
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline-based therapy
Trial: 15990739
Drug: Endovascular implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular implantation of a Medtronic Talent stent graft adjunctive to best medical treatment
Trial: 12551865
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg single oral dose)
Trial: 10097929
Drug: Mix25 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mix25 insulin (36 ± 4 U)
Trial: 10097929
Drug: 30/70 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/70 insulin
Trial: 8906292
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MAOIs-A/B with 5-HTP
Trial: 1867971
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic prophylaxis
Trial: 31088188
Drug: Nilvadipine 8
RxNorm normalized name: nilvadipine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 8 mg/day
Trial: 25050518
Drug: Curcuminoids (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoids (1,500 mg/day in 3 divided doses; n=19)
Trial: 24447437
Drug: Seven-valent pneumococcal
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-valent pneumococcal conjugate vaccine (PCV-7)
Trial: 18604047
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg/kg)
Trial: 24858149
Drug: Labetalol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.25 mg/kg)
Trial: 8342183
Drug: Intravenous glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycerol (500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days)
Trial: 8342183
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (saline)
Trial: 25028357
Drug: IVB+TRP (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVB+TRP (1.25 mg IVB combined with targeted retinal photocoagulation)
Trial: 23084240
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 0.5 mg monthly (0.5q4)
Trial: 23084240
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 2 mg monthly (2q4)
Trial: 23084240
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 2 mg every 2 months after 3 initial monthly doses (2q8)
Trial: 23084240
Drug: Monthly ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly ranibizumab 0.5 mg (Rq4)
Trial: 15770890
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and combined chemoradiation
Trial: 15770890
Drug: Various combined
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation
Trial: 15770890
Drug: Vaccines, antisense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccines, antisense therapy, and proteasome inhibitors
Trial: 12579101
Drug: Heparin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (bolus of 1 mg/kg)
Trial: 2177507
Drug: Systemic interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic interferon and/or podophyllin treatment
Trial: 6996816
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg BID cephradine